Shopping Cart 0
Cart Subtotal
AED 0

LATIN AMERICA ALZHEIMERS DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 5505

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 8074

Details

MARKET OUTLOOK

Triton Market Research envisions that the Alzheimer's disease therapeutics & diagnostics market in Latin America would witness a compound annual growth rate of 7.11% over the forecast period of 2019-2027.

Brazil, Mexico and countries forming rest of Latin America have been scrutinized in the report on Latin America's Alzheimer's disease therapeutics & diagnostics market. Alzheimer's disease refers to the type of dementia that causes problems with thinking, behavior and memory of an individual. Alzheimer's is a progressive disease that destroys the mental function and memory having main symptoms such as confusion and memory loss.

The key driver for the growth of the Alzheimer's disease therapeutics and diagnostics market is the high prevalence of Alzheimer's disease, which emphasizes the need to develop an effective Alzheimer's disease treatment. The elderly generally tend to suffer from Alzheimer's, which is a progressive and irreversible brain disorder that gradually damages an individual's thinking skills, memory and eventually even destroys the capability to perform the simplest of daily tasks. Alzheimer's disease is the primary reason for dementia among the aged population, which is a normal part of the aging process. Thus, the rising geriatric population acts as a major driver for the Alzheimer's disease therapeutics and diagnostics market.

According to the Alzheimer's Organization, despite a substantial number of people being impacted by Alzheimer's, a large part of the population still lacks knowledge about this disease. Hence, it is critical to create awareness about AD. The younger onset of Alzheimer's disease that strikes the individuals aged below 65 years, coupled with the lack of public awareness is considered as the major reason for minimal public sympathy, insufficient resources related to addressing the effective diagnosis and treatment of AD. Compared to any other diseases such as cancer, diabetes, hypertension, etc. Alzheimer's disease is more likely to be misperceived as any normal part of the aging process. Moreover, the diagnosis of Alzheimer's brings along with it the stigma and social isolation which also proves to be a challenge for opting for the effective and timely diagnostics and treatment of the disease. Hence, the lack of awareness regarding new therapies that are used for the treatment of Alzheimer's disease act as a significant growth challenge for the Alzheimer's disease treatment and diagnostics market over the forecast period.

 

COMPETITIVE OUTLOOK

Piramal Enterprises, Ltd., Biogen, Inc., Siemens Medical Solutions, GE Healthcare, F. Hoffmann-La Roche AG, Baxter International, Inc., Sun Pharma, Merck And Co., AbbVie, Inc. and Pfizer, Inc. are some of the prominent companies in the Alzheimer's disease therapeutics & diagnostics market.

READ MORE

Table Of Content

Scope

TABLE OF CONTENTS

1. LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET-SUMMARY

2. INDUSTRY OUTLOOK

2.1. MARKET DEFINITION

2.2. PORTER'S FIVE FORCE MODEL

2.2.1. THREAT OF NEW ENTRANTS

2.2.2. THREATS OF SUBSTITUTE PRODUCT

2.2.3. BARGAINING POWER OF BUYER

2.2.4. BARGAINING POWER OF SUPPLIER

2.2.5. INTENSITY OF COMPETITIVE RIVALRY

2.3. VENDOR SCORECARD

2.4. ETYMOLOGY

2.5. PARENT MARKET OUTLOOK

2.6. STRATEGIC BUYING CRITERIA OUTLOOK

2.7. INVESTMENTS OUTLOOK

2.8. KEY FINDINGS

2.9. INDUSTRY STRUCTURE

2.9.1. RESEARCH & DEVELOPMENT

2.9.2. MANUFACTURING

2.9.3. RAW MATERIALS

2.9.4. END-USER

2.9.5. WHOLESALERS

2.10. ALZHEIMER'S DISEASE ETIOLOGY

2.11. PIPELINE OUTLOOK

2.12. PHASES AND STERNNESS OF ALZHEIMER'S DISEASE

2.13. MARKET DRIVERS

2.13.1. GROWTH OF ALZHEIMER'S DISEASE

2.13.2. RISE IN GERIATRIC POPULATION

2.13.3. SUBSTANTIAL INVESTMENTS BY GOVERNMENT IN RESEARCH

2.14. MARKET RESTRAINTS

2.14.1. STRINGENT GOVERNMENT REGULATIONS

2.14.2. HIGH TREATMENT COSTS OF ALZHEIMER'S DISEASE

2.15. MARKET OPPORTUNITIES

2.15.1. IN-VITRO DIAGNOSTIC TECHNIQUES ARE A BOON TO THE MARKET

2.15.2. R&D INVESTMENT IN PERSONALIZED MEDICINES IS INCREASING

2.16. MARKET CHALLENGES

2.16.1. LESS AWARENESS CONCERNING NEW THERAPIES IN ALZHEIMER'S DISEASE

2.16.2. VERY FEW SKILLED PROFESSIONALS PERTAINING TO THE TREATMENT OF ALZHEIMER'S DISEASE

3. ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET OUTLOOK-BY THERAPEUTICS AND DIAGNOSTICS

3.1. THERAPEUTICS

3.1.1. THERAPEUTICS BY DRUGS

3.1.1.1. MARKETED DRUGS

3.1.1.2. PIPELINE DRUGS

3.1.2. THERAPEUTICS BY DISEASE STAGE

3.1.2.1. LATE STAGE: SEVERE AD

3.1.2.2. EARLY/MIDDLE STAGE: MILD TO MODERATE AD

3.1.2.3. PRODROMAL STAGE

3.1.3. THERAPEUTICS BY GENERIC AND BRANDED

3.1.3.1. BRANDED

3.1.3.2. GENERIC

3.2. DIAGNOSTICS

3.2.1. LUMBAR PUNCTURE TEST

3.2.2. POSITRON EMISSION TOMOGRAPHY

3.2.3. ELECTROENCEPHALOGRAPHY

3.2.4. MAGNETIC RESONANCE IMAGING

3.2.5. COMPUTED TOMOGRAPHY

3.2.6. OTHER DIAGNOSTICS

4. ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET-REGIONAL OUTLOOK

4.1.1. COUNTRY ANALYSIS

4.1.1.1. BRAZIL

4.1.1.2. MEXICO

4.1.1.3. REST OF LATIN AMERICA

5. COMPETITIVE LANDSCAPE

5.1. ABBVIE, INC.

5.2. BAXTER INTERNATIONAL, INC.

5.3. BIOGEN, INC.

5.4. F. HOFFMANN-LA ROCHE AG

5.5. GE HEALTHCARE

5.6. MERCK AND CO.

5.7. PFIZER, INC.

5.8. PIRAMAL ENTERPRISES, LTD.

5.9. SIEMENS MEDICAL SOLUTIONS

5.10. SUN PHARMA

6. METHODOLOGY AND SCOPE

6.1. RESEARCH SCOPE

6.2. SOURCES OF DATA

6.3. RESEARCH METHODOLOGY

 

 

 

 

TABLE LIST

TABLE 1 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

TABLE 2 DIFFERENT BIOMARKERS RELATED TO ALZHEIMER'S DISEASE

TABLE 3 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS, BY DRUGS, 2019-2027 (USD MILLION)

TABLE 4 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN DISEASE STAGE, BY DRUGS, 2019-2027 (USD MILLION)

TABLE 5 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS, BY GENERIC AND BRANDED, 2019-2027 (USD MILLION)

TABLE 6 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY TYPES, 2019-2027 (USD MILLION)

TABLE 7 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, 2019-2027 (USD MILLION)

 

 

 

 

FIGURE LIST

FIGURE 1 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

FIGURE 2 ALZHEIMER'S DRUGS IN THE PIPELINE BY TREATMENT FOCUS (NUMBER OF DRUGS)

FIGURE 3 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS 2019-2027 (USD MILLION)

FIGURE 4 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN MARKETED DRUGS 2019-2027 (USD MILLION)

FIGURE 5 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN PIPELINE DRUGS 2019-2027 (USD MILLION)

FIGURE 6 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN LATE STAGE: SEVERE AD 2019-2027 (USD MILLION)

FIGURE 7 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN EARLY/MIDDLE STAGE: MILD TO MODERATE AD 2019-2027 (USD MILLION)

FIGURE 8 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN PRODROMAL STAGE 2019-2027 (USD MILLION)

FIGURE 9 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN BRANDED 2019-2027 (USD MILLION)

FIGURE 10 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN GENERIC 2019-2027 (USD MILLION)

FIGURE 11 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN DIAGNOSTICS 2019-2027 (USD MILLION)

FIGURE 12 LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN LUMBAR PUNCTURE TEST 2019-2027 (USD MILLION)

FIGURE 13 LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN POSITRON EMISSION TOMOGRAPHY 2019-2027 (USD MILLION)

FIGURE 14 LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN ELECTROENCEPHALOGRAPHY 2019-2027 (USD MILLION)

FIGURE 15 LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN MAGNETIC RESONANCE IMAGING 2019-2027 (USD MILLION)

FIGURE 16 LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN COMPUTED TOMOGRAPHY 2019-2027 (USD MILLION)

FIGURE 17 LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN OTHER DIAGNOSTICS 2019-2027 (USD MILLION)

FIGURE 18 BRAZIL ALZHEIMER'S DISEASE DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

FIGURE 19 MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

FIGURE 20 REST OF LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET 2019-2027 (USD MILLION)


List Of Figure

FIGURE LIST

FIGURE 1 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

FIGURE 2 ALZHEIMER'S DRUGS IN THE PIPELINE BY TREATMENT FOCUS (NUMBER OF DRUGS)

FIGURE 3 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS 2019-2027 (USD MILLION)

FIGURE 4 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN MARKETED DRUGS 2019-2027 (USD MILLION)

FIGURE 5 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN PIPELINE DRUGS 2019-2027 (USD MILLION)

FIGURE 6 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN LATE STAGE: SEVERE AD 2019-2027 (USD MILLION)

FIGURE 7 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN EARLY/MIDDLE STAGE: MILD TO MODERATE AD 2019-2027 (USD MILLION)

FIGURE 8 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN PRODROMAL STAGE 2019-2027 (USD MILLION)

FIGURE 9 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN BRANDED 2019-2027 (USD MILLION)

FIGURE 10 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN GENERIC 2019-2027 (USD MILLION)

FIGURE 11 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN DIAGNOSTICS 2019-2027 (USD MILLION)

FIGURE 12 LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN LUMBAR PUNCTURE TEST 2019-2027 (USD MILLION)

FIGURE 13 LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN POSITRON EMISSION TOMOGRAPHY 2019-2027 (USD MILLION)

FIGURE 14 LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN ELECTROENCEPHALOGRAPHY 2019-2027 (USD MILLION)

FIGURE 15 LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN MAGNETIC RESONANCE IMAGING 2019-2027 (USD MILLION)

FIGURE 16 LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN COMPUTED TOMOGRAPHY 2019-2027 (USD MILLION)

FIGURE 17 LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN OTHER DIAGNOSTICS 2019-2027 (USD MILLION)

FIGURE 18 BRAZIL ALZHEIMER'S DISEASE DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

FIGURE 19 MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

FIGURE 20 REST OF LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET 2019-2027 (USD MILLION)


List Of Table

TABLE LIST

TABLE 1 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

TABLE 2 DIFFERENT BIOMARKERS RELATED TO ALZHEIMER'S DISEASE

TABLE 3 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS, BY DRUGS, 2019-2027 (USD MILLION)

TABLE 4 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN DISEASE STAGE, BY DRUGS, 2019-2027 (USD MILLION)

TABLE 5 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS, BY GENERIC AND BRANDED, 2019-2027 (USD MILLION)

TABLE 6 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY TYPES, 2019-2027 (USD MILLION)

TABLE 7 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, 2019-2027 (USD MILLION)

Licence Rights

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies


Companies

1. ABBVIE, INC.

2. BAXTER INTERNATIONAL, INC.

3. BIOGEN, INC.

4. F. HOFFMANN-LA ROCHE AG

5. GE HEALTHCARE

6. MERCK AND CO.

7. PFIZER, INC.

8. PIRAMAL ENTERPRISES, LTD.

9. SIEMENS MEDICAL SOLUTIONS

10. SUN PHARMA

Company Profile

Company Profile Title

MARKET OUTLOOK

Triton Market Research envisions that the Alzheimer's disease therapeutics & diagnostics market in Latin America would witness a compound annual growth rate of 7.11% over the forecast period of 2019-2027.

Brazil, Mexico and countries forming rest of Latin America have been scrutinized in the report on Latin America's Alzheimer's disease therapeutics & diagnostics market. Alzheimer's disease refers to the type of dementia that causes problems with thinking, behavior and memory of an individual. Alzheimer's is a progressive disease that destroys the mental function and memory having main symptoms such as confusion and memory loss.

The key driver for the growth of the Alzheimer's disease therapeutics and diagnostics market is the high prevalence of Alzheimer's disease, which emphasizes the need to develop an effective Alzheimer's disease treatment. The elderly generally tend to suffer from Alzheimer's, which is a progressive and irreversible brain disorder that gradually damages an individual's thinking skills, memory and eventually even destroys the capability to perform the simplest of daily tasks. Alzheimer's disease is the primary reason for dementia among the aged population, which is a normal part of the aging process. Thus, the rising geriatric population acts as a major driver for the Alzheimer's disease therapeutics and diagnostics market.

According to the Alzheimer's Organization, despite a substantial number of people being impacted by Alzheimer's, a large part of the population still lacks knowledge about this disease. Hence, it is critical to create awareness about AD. The younger onset of Alzheimer's disease that strikes the individuals aged below 65 years, coupled with the lack of public awareness is considered as the major reason for minimal public sympathy, insufficient resources related to addressing the effective diagnosis and treatment of AD. Compared to any other diseases such as cancer, diabetes, hypertension, etc. Alzheimer's disease is more likely to be misperceived as any normal part of the aging process. Moreover, the diagnosis of Alzheimer's brings along with it the stigma and social isolation which also proves to be a challenge for opting for the effective and timely diagnostics and treatment of the disease. Hence, the lack of awareness regarding new therapies that are used for the treatment of Alzheimer's disease act as a significant growth challenge for the Alzheimer's disease treatment and diagnostics market over the forecast period.

 

COMPETITIVE OUTLOOK

Piramal Enterprises, Ltd., Biogen, Inc., Siemens Medical Solutions, GE Healthcare, F. Hoffmann-La Roche AG, Baxter International, Inc., Sun Pharma, Merck And Co., AbbVie, Inc. and Pfizer, Inc. are some of the prominent companies in the Alzheimer's disease therapeutics & diagnostics market.

READ MORE

Scope

TABLE OF CONTENTS

1. LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET-SUMMARY

2. INDUSTRY OUTLOOK

2.1. MARKET DEFINITION

2.2. PORTER'S FIVE FORCE MODEL

2.2.1. THREAT OF NEW ENTRANTS

2.2.2. THREATS OF SUBSTITUTE PRODUCT

2.2.3. BARGAINING POWER OF BUYER

2.2.4. BARGAINING POWER OF SUPPLIER

2.2.5. INTENSITY OF COMPETITIVE RIVALRY

2.3. VENDOR SCORECARD

2.4. ETYMOLOGY

2.5. PARENT MARKET OUTLOOK

2.6. STRATEGIC BUYING CRITERIA OUTLOOK

2.7. INVESTMENTS OUTLOOK

2.8. KEY FINDINGS

2.9. INDUSTRY STRUCTURE

2.9.1. RESEARCH & DEVELOPMENT

2.9.2. MANUFACTURING

2.9.3. RAW MATERIALS

2.9.4. END-USER

2.9.5. WHOLESALERS

2.10. ALZHEIMER'S DISEASE ETIOLOGY

2.11. PIPELINE OUTLOOK

2.12. PHASES AND STERNNESS OF ALZHEIMER'S DISEASE

2.13. MARKET DRIVERS

2.13.1. GROWTH OF ALZHEIMER'S DISEASE

2.13.2. RISE IN GERIATRIC POPULATION

2.13.3. SUBSTANTIAL INVESTMENTS BY GOVERNMENT IN RESEARCH

2.14. MARKET RESTRAINTS

2.14.1. STRINGENT GOVERNMENT REGULATIONS

2.14.2. HIGH TREATMENT COSTS OF ALZHEIMER'S DISEASE

2.15. MARKET OPPORTUNITIES

2.15.1. IN-VITRO DIAGNOSTIC TECHNIQUES ARE A BOON TO THE MARKET

2.15.2. R&D INVESTMENT IN PERSONALIZED MEDICINES IS INCREASING

2.16. MARKET CHALLENGES

2.16.1. LESS AWARENESS CONCERNING NEW THERAPIES IN ALZHEIMER'S DISEASE

2.16.2. VERY FEW SKILLED PROFESSIONALS PERTAINING TO THE TREATMENT OF ALZHEIMER'S DISEASE

3. ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET OUTLOOK-BY THERAPEUTICS AND DIAGNOSTICS

3.1. THERAPEUTICS

3.1.1. THERAPEUTICS BY DRUGS

3.1.1.1. MARKETED DRUGS

3.1.1.2. PIPELINE DRUGS

3.1.2. THERAPEUTICS BY DISEASE STAGE

3.1.2.1. LATE STAGE: SEVERE AD

3.1.2.2. EARLY/MIDDLE STAGE: MILD TO MODERATE AD

3.1.2.3. PRODROMAL STAGE

3.1.3. THERAPEUTICS BY GENERIC AND BRANDED

3.1.3.1. BRANDED

3.1.3.2. GENERIC

3.2. DIAGNOSTICS

3.2.1. LUMBAR PUNCTURE TEST

3.2.2. POSITRON EMISSION TOMOGRAPHY

3.2.3. ELECTROENCEPHALOGRAPHY

3.2.4. MAGNETIC RESONANCE IMAGING

3.2.5. COMPUTED TOMOGRAPHY

3.2.6. OTHER DIAGNOSTICS

4. ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET-REGIONAL OUTLOOK

4.1.1. COUNTRY ANALYSIS

4.1.1.1. BRAZIL

4.1.1.2. MEXICO

4.1.1.3. REST OF LATIN AMERICA

5. COMPETITIVE LANDSCAPE

5.1. ABBVIE, INC.

5.2. BAXTER INTERNATIONAL, INC.

5.3. BIOGEN, INC.

5.4. F. HOFFMANN-LA ROCHE AG

5.5. GE HEALTHCARE

5.6. MERCK AND CO.

5.7. PFIZER, INC.

5.8. PIRAMAL ENTERPRISES, LTD.

5.9. SIEMENS MEDICAL SOLUTIONS

5.10. SUN PHARMA

6. METHODOLOGY AND SCOPE

6.1. RESEARCH SCOPE

6.2. SOURCES OF DATA

6.3. RESEARCH METHODOLOGY

 

 

 

 

TABLE LIST

TABLE 1 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

TABLE 2 DIFFERENT BIOMARKERS RELATED TO ALZHEIMER'S DISEASE

TABLE 3 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS, BY DRUGS, 2019-2027 (USD MILLION)

TABLE 4 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN DISEASE STAGE, BY DRUGS, 2019-2027 (USD MILLION)

TABLE 5 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS, BY GENERIC AND BRANDED, 2019-2027 (USD MILLION)

TABLE 6 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY TYPES, 2019-2027 (USD MILLION)

TABLE 7 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, 2019-2027 (USD MILLION)

 

 

 

 

FIGURE LIST

FIGURE 1 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

FIGURE 2 ALZHEIMER'S DRUGS IN THE PIPELINE BY TREATMENT FOCUS (NUMBER OF DRUGS)

FIGURE 3 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS 2019-2027 (USD MILLION)

FIGURE 4 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN MARKETED DRUGS 2019-2027 (USD MILLION)

FIGURE 5 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN PIPELINE DRUGS 2019-2027 (USD MILLION)

FIGURE 6 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN LATE STAGE: SEVERE AD 2019-2027 (USD MILLION)

FIGURE 7 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN EARLY/MIDDLE STAGE: MILD TO MODERATE AD 2019-2027 (USD MILLION)

FIGURE 8 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN PRODROMAL STAGE 2019-2027 (USD MILLION)

FIGURE 9 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN BRANDED 2019-2027 (USD MILLION)

FIGURE 10 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN GENERIC 2019-2027 (USD MILLION)

FIGURE 11 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN DIAGNOSTICS 2019-2027 (USD MILLION)

FIGURE 12 LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN LUMBAR PUNCTURE TEST 2019-2027 (USD MILLION)

FIGURE 13 LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN POSITRON EMISSION TOMOGRAPHY 2019-2027 (USD MILLION)

FIGURE 14 LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN ELECTROENCEPHALOGRAPHY 2019-2027 (USD MILLION)

FIGURE 15 LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN MAGNETIC RESONANCE IMAGING 2019-2027 (USD MILLION)

FIGURE 16 LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN COMPUTED TOMOGRAPHY 2019-2027 (USD MILLION)

FIGURE 17 LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN OTHER DIAGNOSTICS 2019-2027 (USD MILLION)

FIGURE 18 BRAZIL ALZHEIMER'S DISEASE DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

FIGURE 19 MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

FIGURE 20 REST OF LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET 2019-2027 (USD MILLION)


List Of Figure

FIGURE LIST

FIGURE 1 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

FIGURE 2 ALZHEIMER'S DRUGS IN THE PIPELINE BY TREATMENT FOCUS (NUMBER OF DRUGS)

FIGURE 3 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS 2019-2027 (USD MILLION)

FIGURE 4 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN MARKETED DRUGS 2019-2027 (USD MILLION)

FIGURE 5 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN PIPELINE DRUGS 2019-2027 (USD MILLION)

FIGURE 6 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN LATE STAGE: SEVERE AD 2019-2027 (USD MILLION)

FIGURE 7 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN EARLY/MIDDLE STAGE: MILD TO MODERATE AD 2019-2027 (USD MILLION)

FIGURE 8 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN PRODROMAL STAGE 2019-2027 (USD MILLION)

FIGURE 9 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN BRANDED 2019-2027 (USD MILLION)

FIGURE 10 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN GENERIC 2019-2027 (USD MILLION)

FIGURE 11 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN DIAGNOSTICS 2019-2027 (USD MILLION)

FIGURE 12 LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN LUMBAR PUNCTURE TEST 2019-2027 (USD MILLION)

FIGURE 13 LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN POSITRON EMISSION TOMOGRAPHY 2019-2027 (USD MILLION)

FIGURE 14 LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN ELECTROENCEPHALOGRAPHY 2019-2027 (USD MILLION)

FIGURE 15 LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN MAGNETIC RESONANCE IMAGING 2019-2027 (USD MILLION)

FIGURE 16 LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN COMPUTED TOMOGRAPHY 2019-2027 (USD MILLION)

FIGURE 17 LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN OTHER DIAGNOSTICS 2019-2027 (USD MILLION)

FIGURE 18 BRAZIL ALZHEIMER'S DISEASE DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

FIGURE 19 MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

FIGURE 20 REST OF LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET 2019-2027 (USD MILLION)


List Of Table

TABLE LIST

TABLE 1 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

TABLE 2 DIFFERENT BIOMARKERS RELATED TO ALZHEIMER'S DISEASE

TABLE 3 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS, BY DRUGS, 2019-2027 (USD MILLION)

TABLE 4 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN DISEASE STAGE, BY DRUGS, 2019-2027 (USD MILLION)

TABLE 5 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS, BY GENERIC AND BRANDED, 2019-2027 (USD MILLION)

TABLE 6 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY TYPES, 2019-2027 (USD MILLION)

TABLE 7 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, 2019-2027 (USD MILLION)

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS


Companies

1. ABBVIE, INC.

2. BAXTER INTERNATIONAL, INC.

3. BIOGEN, INC.

4. F. HOFFMANN-LA ROCHE AG

5. GE HEALTHCARE

6. MERCK AND CO.

7. PFIZER, INC.

8. PIRAMAL ENTERPRISES, LTD.

9. SIEMENS MEDICAL SOLUTIONS

10. SUN PHARMA